科兴生物回应纳斯达克退市通知：将尽快完成2024年年报提交工作，并要求进行听证申辩会

Core Viewpoint - The company, Sinovac Biotech, has received a delisting notice from NASDAQ due to its failure to submit the annual report for the fiscal year ending December 31, 2024, by the extended deadline [1][2] Group 1: Delisting Notice and Response - On November 12, 2025, Sinovac received a delisting decision letter from NASDAQ's Listing Qualifications Department [1] - The company has engaged UHY LLP as its new independent auditor to expedite the submission of the 2024 annual report and restore compliance with listing rules [1] - Sinovac plans to request an extension for the annual report submission and will seek a hearing regarding the delisting matter [2] Group 2: Business Operations and Governance Issues - Sinovac stated that its U.S. listing status will not materially affect its core business operations, which continue normally, including vaccine research, production, and supply [3] - Internal governance issues have plagued the company for years, leading to a prolonged stock suspension and a precarious listing status [4][6] - A special shareholders' meeting held on July 9, 2023, resulted in the removal of the current board, with new members appointed, but faced resistance from the existing chairman [4] Group 3: Financial Matters - The company announced a $7.448 billion dividend plan, with an initial payment of $55 per share, which could deplete over 70% of its cash reserves [4] - The special cash dividend was distributed to legal shareholders, with significant amounts going to major stakeholders [5]